A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...

Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

A new lipid nanoparticle could make mRNA vaccines more powerful and potentially lower the cost per vaccine dose.

The team used the AMG1541 LNP to deliver an mRNA influenza vaccine in mice. They compared this vaccine’s effectiveness to a flu vaccine made with the lipid SM-102, which is FDA-approved and was used ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Feb 12 (Reuters) - Vaccine makers are shoring up their supply of a critical raw material in "messenger RNA" vaccines: the lipid molecules that help deliver the genetic RNA material into cells.

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel highlighted various alleged “safety uncertainties” of the mRNA COVID-19 ...